

26 September 2021

Superior Effectiveness of Fludrocortisone Acetate Confirmed in Peer Reviewed Journal.

The publication of a pre-clinical study in the **Journal of Experimental Eye Research** this month, titled:

“Anti-inflammatory and neuroprotective properties of the corticosteroid fludrocortisone in retinal degeneration”

confirmed the effectiveness of **Fludrocortisone (FA)** in the treatment of macular atrophy associated with **wet Age-Related Macular Degeneration (AMD)** in animal models.

The study also demonstrated the potential of FA in the treatment of **Geographic Atrophy (GA)** associated with late stage dry -AMD for which no treatment is currently available.

The study was completed at the Australian National University and funded by the NH&MRC and the Gordon & Gretel Bootes Foundation. A copy of the paper is attached for your reference.

The authors concluded that:

“..... FA may be an efficacious strategy for ameliorating neurodegeneration implicated in such disorders.”

Eye Co holds several patents associated with FA in the treatment of retinal diseases which have either been granted or under examination in various major jurisdictions around the world.

Eye Co has just completed a safety study involving the first use of FA in humans and results are currently being analysed.

Eye Co is in the business of identifying and completing early-stage development of treatments for retinal diseases. The company intends to out-license its technologies to commercialisation partners with the resources and capability to bring these technologies to patients globally. The publication of this study will significantly facilitate this process

Yours sincerely



Peter Abrahamson
Managing Director